Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab (IBI306) in Hypercholesterolemia (CREDIT-4)
NCT04709536Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2021
- Primary completion
- Nov 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in hypercholesterolemia, sponsored by Innovent Biologics. Started Feb 2021; status: completed.
02
Drugs
tafolecimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04709536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04709536.